ALR Technologies Inc. (ALRT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALR Technologies Inc. (ALRT) trades at $0.03 with AI Score 56/100 (Grade B). ALR Technologies Inc. develops and markets diabetes care solutions for both human and animal health. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ALRT: ALRT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALRT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ALRT: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →ALR Technologies Inc. (ALRT) Healthcare & Pipeline Overview
ALR Technologies Inc. provides diabetes care solutions, including data management systems and continuous glucose monitoring, targeting healthcare providers, insurers, and disease management services. With a focus on both human and animal health, ALRT operates in the medical devices sector, offering tools for diabetes and prediabetes management.
What Is the Investment Thesis for ALRT?
ALR Technologies Inc. operates in the growing diabetes care market, offering solutions for both humans and animals. The company's Diabetes Management System and CGM devices address the increasing need for effective diabetes management tools. A potential growth catalyst is the expansion of their GluCurve Pet CGM into the veterinary market, tapping into the rising demand for animal healthcare solutions. However, the company's negative P/E ratio of -1.35 and a substantial negative profit margin of -159306.4% raise concerns about its financial sustainability. Investors should closely monitor ALRT's ability to improve profitability and expand its market reach to achieve long-term growth.
Based on FMP financials and quantitative analysis
ALRT Key Highlights
- Gross Margin of 66.2% indicates a strong ability to control production costs relative to revenue.
- Beta of 0.37 suggests the stock is less volatile than the overall market.
- The company's focus on both human and animal diabetes care provides diversification within the healthcare sector.
- ALR Technologies' Diabetes Management System offers a comprehensive approach to diabetes care, potentially attracting a wide range of customers.
- The company's Prediabetes System addresses a growing market segment focused on preventative care.
Who Are ALRT's Competitors?
ALRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.47M | 46 |
| ATBPF Antibe Therapeutics Inc. | $0.22 | -0.19% | $11.43M | 44 |
| DIZTF Dignitana AB (publ) | $0.22 | +0.00% | $17.99M | 49 |
| LXXGF LexaGene Holdings Inc. | $0.08 | +0.00% | $11.34M | 53 |
| MNNDF Nurosene Health Inc. | $0.33 | -8.71% | $14.25M | 46 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALRT's Key Strengths?
- Comprehensive Diabetes Management System.
- Specialized GluCurve Pet CGM for animal health.
- Focus on both human and animal diabetes care.
- Established relationships with healthcare providers.
What Are ALRT's Weaknesses?
- Negative P/E ratio and profit margin.
- Limited market share compared to larger competitors.
- Small number of employees.
- Dependence on a limited number of products and services.
What Could Drive ALRT Stock Higher?
- Expansion of GluCurve Pet CGM into the veterinary market, driven by increasing pet ownership and awareness of pet health.
- Strategic partnerships with healthcare providers to integrate Diabetes Management System into existing platforms.
- Development of advanced CGM technology with real-time data analysis and predictive alerts.
- Expansion into international markets with high diabetes prevalence and growing healthcare infrastructure.
- Focus on Prediabetes Management Programs to address the rising prevalence of prediabetes.
What Are the Key Risks for ALRT?
- Intense competition from established medical device companies in the diabetes care market.
- Regulatory changes affecting diabetes care products and reimbursement policies.
- Economic downturn impacting healthcare spending and demand for diabetes management solutions.
- Technological obsolescence of existing products due to rapid advancements in glucose monitoring technology.
- The company's negative P/E ratio and profit margin raise concerns about its financial sustainability.
What Are the Growth Opportunities for ALRT?
- Expansion of GluCurve Pet CGM in the Veterinary Market: The market for pet diabetes care is growing, presenting a significant opportunity for ALR Technologies to expand its GluCurve Pet CGM product. With the increasing pet ownership and rising awareness of pet health, the demand for diabetes management solutions for animals is expected to rise. ALRT can leverage this trend by targeting veterinary clinics and pet owners, offering a specialized solution for feline and canine diabetes care. The market size for pet diabetes care is estimated to reach $1.2 billion by 2028, providing a substantial growth avenue for ALRT.
- Strategic Partnerships with Healthcare Providers: Collaborating with healthcare providers and hospitals can enhance ALR Technologies' market reach and customer base. By integrating its Diabetes Management System into healthcare providers' existing platforms, ALRT can offer a seamless solution for diabetes management. These partnerships can also facilitate the adoption of ALRT's products among a wider patient population. The market for diabetes management solutions in healthcare settings is projected to grow at a CAGR of 8% over the next five years, driven by the increasing focus on value-based care and remote patient monitoring.
- Development of Advanced CGM Technology: Investing in the development of next-generation Continuous Glucose Monitoring (CGM) technology can provide ALR Technologies with a competitive edge. By incorporating advanced features such as real-time data analysis, predictive alerts, and integration with insulin delivery systems, ALRT can attract a larger customer base. The CGM market is expected to reach $10 billion by 2027, driven by technological advancements and the increasing demand for convenient and accurate glucose monitoring solutions. ALRT can capitalize on this trend by offering innovative CGM devices that meet the evolving needs of diabetes patients.
- Expansion into International Markets: Expanding into international markets can significantly increase ALR Technologies' revenue and market share. By targeting countries with a high prevalence of diabetes and a growing healthcare infrastructure, ALRT can tap into new customer segments. The global diabetes care market is projected to reach $150 billion by 2025, with significant growth opportunities in emerging economies. ALRT can leverage its existing product portfolio and adapt its solutions to meet the specific needs of different international markets.
- Focus on Prediabetes Management Programs: With the rising prevalence of prediabetes, there is a growing demand for effective prevention and management programs. ALR Technologies can capitalize on this trend by expanding its Prediabetes System and offering comprehensive solutions that include educational content, lifestyle coaching, and remote monitoring. The market for prediabetes management is expected to grow at a CAGR of 10% over the next five years, driven by the increasing awareness of the importance of early intervention. ALRT can leverage its expertise in data management and diabetes care to develop innovative prediabetes management programs that attract a wide range of customers.
What Opportunities Does ALRT Have?
- Expansion of GluCurve Pet CGM in the veterinary market.
- Strategic partnerships with healthcare providers.
- Development of advanced CGM technology.
- Expansion into international markets.
What Threats Does ALRT Face?
- Intense competition from established medical device companies.
- Regulatory changes affecting diabetes care products.
- Economic downturn impacting healthcare spending.
- Technological obsolescence of existing products.
What Are ALRT's Competitive Advantages?
- Proprietary Diabetes Management System with integrated data collection and analysis.
- Specialized GluCurve Pet CGM addressing a niche market in veterinary medicine.
- Established relationships with healthcare providers and insurers.
- Focus on both human and animal health provides diversification.
What Does ALRT Do?
ALR Technologies Inc., established in 1987 and based in Richmond, Virginia, is a data management company focused on developing diabetes care solutions. Originally named Mo Betta Corp. before changing its name in 1998, ALRT provides a range of products and services aimed at improving diabetes management for both humans and animals. Their flagship product, the Diabetes Management System, offers a comprehensive approach that includes data collection, predictive A1C, insulin dosage adjustment suggestions, performance tracking, and remote monitoring. The company also provides Continuous Glucose Monitoring (CGM) devices for real-time blood sugar readings and GluCurve Pet CGM, catering to the veterinary market for feline and canine diabetes care. Additionally, ALRT offers a Prediabetes System, featuring educational content and a private online community, designed to help patients manage and prevent the onset of diabetes. ALR Technologies primarily targets healthcare providers, health insurance companies, and disease and case management services, including the home care industry, with its integrated diabetes care solutions.
What Products and Services Does ALRT Offer?
- Develops Diabetes Management System for data collection and performance tracking.
- Offers predictive A1C and insulin dosage adjustment suggestions.
- Provides Continuous Glucose Monitoring (CGM) devices for blood sugar readings.
- Offers GluCurve Pet CGM for diabetes care in felines and canines.
- Provides Prediabetes System with educational videos and online community.
- Targets healthcare providers, health insurers, and disease management services.
How Does ALRT Make Money?
- Sells Diabetes Management System subscriptions to healthcare providers and insurers.
- Generates revenue from the sale of Continuous Glucose Monitoring (CGM) devices.
- Offers GluCurve Pet CGM to veterinary clinics and pet owners.
- Provides Prediabetes System subscriptions to individuals at risk of developing diabetes.
What Industry Does ALRT Operate In?
ALR Technologies Inc. operates within the medical devices industry, specifically focusing on diabetes care solutions. The market for diabetes management is expanding due to the increasing prevalence of diabetes globally. Competitors include companies like AMHV, ATBPF, DIZTF, LXXGF, and MNNDF, which offer various diabetes monitoring and treatment solutions. The industry is driven by technological advancements in glucose monitoring and insulin delivery systems, as well as the growing demand for personalized and remote patient care.
Who Are ALRT's Key Customers?
- Healthcare providers managing diabetes patients.
- Health insurance companies covering diabetes care.
- Veterinary clinics treating diabetic pets.
- Individuals with diabetes or prediabetes.
ROE 52%Key Financial Metrics
Return on equity for ALR Technologies Inc. stands at 51.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -74.1%, the inverse of the P/E and a quick read on earnings relative to price.
ALR Technologies Inc. (ALRT) Valuation Context
Relative to its peer group, ALRT's quantitative score of 56/100 is roughly in line with the peer average of 48/100.
Company Profile
ALR Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Richmond, US. The company is led by CEO Sidney S. Chan. ALRT has traded publicly since 2000.
ALRT Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in ALRT's future, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative health monitoring solutions gaining traction.
- Market perception is improving as ALRT is increasingly recognized for its role in digital health, aligning with broader industry trends.
- Recent partnerships announced by ALRT have generated excitement, as they could enhance market reach and product offerings.
Bear Case
- Despite the positive sentiment, some analysts express concerns about ALRT's competitive positioning in a rapidly evolving market.
- There are lingering doubts about the scalability of ALRT's technology, with some community members questioning its practicality in real-world applications.
- Recent financial disclosures raised eyebrows, as some investors are wary of the company’s cash flow management and operational efficiency.
- Market volatility in the tech sector has led to a cautious approach among investors, with ALRT being viewed as a higher-risk proposition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ALRT Latest News
No recent news available for ALRT.
ALRT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALRT.
Price Targets
Wall Street price target analysis for ALRT.
ALRT MoonshotScore
What does this score mean?
The MoonshotScore rates ALRT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sidney S. Chan
CEO
Sidney S. Chan is the CEO of ALR Technologies Inc. His background includes extensive experience in managing and growing technology-driven companies. He has a proven track record in strategic planning, business development, and financial management. Chan's expertise lies in identifying market opportunities and driving innovation to create value for shareholders. He is committed to building a strong team and fostering a culture of excellence within the organization. His leadership is focused on expanding ALR Technologies' market presence and delivering sustainable growth.
Track Record: Under Sidney S. Chan's leadership, ALR Technologies Inc. has focused on expanding its product portfolio and strengthening its relationships with key customers. He has overseen the development and launch of new products, including the GluCurve Pet CGM, and has implemented strategies to improve operational efficiency and reduce costs. Chan has also focused on building a strong management team and fostering a culture of innovation within the company.
ALRT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. These securities often include those of companies that are distressed, in bankruptcy, or unwilling to provide information to the public. Companies on the OTC Other tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and viability. Investing in OTC Other securities carries significant risks due to the lack of transparency and regulatory oversight compared to securities listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in ALR Technologies Inc.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- The OTC Other tier carries a higher risk of fraud and manipulation compared to major exchanges.
- Lack of regulatory oversight increases the potential for mismanagement and financial irregularities.
- The company's financial stability and long-term viability are uncertain due to the limited information available.
- Verify the company's legal standing and registration.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1987.
- ALR Technologies Inc. focuses on diabetes care, addressing a significant healthcare need.
- The company has a CEO, Sidney S. Chan, indicating leadership and management structure.
What Investors Ask About ALR Technologies Inc. (ALRT) — Healthcare
What does ALR Technologies Inc. do?
ALR Technologies Inc. is a data management company that develops and markets diabetes care solutions for both human and animal health. Their primary product is the Diabetes Management System, a comprehensive tool for data collection, predictive A1C, insulin dosage adjustment, performance tracking, and remote monitoring. They also offer Continuous Glucose Monitoring (CGM) devices for humans and a specialized CGM for pets (GluCurve Pet CGM). Additionally, ALRT provides a Prediabetes System with educational content and a community platform. The company targets healthcare providers, insurers, and disease management services.
What do analysts say about ALRT stock?
As of March 18, 2026, there is no readily available analyst consensus on ALRT stock. Key valuation metrics to consider include the company's negative P/E ratio of -1.35 and a negative profit margin of -159306.4%. Growth considerations revolve around the company's ability to expand its market reach, particularly with its GluCurve Pet CGM, and to improve its financial performance. Investors should conduct their own due diligence and consider the risks associated with investing in OTC-listed companies.
What are the main risks for ALRT?
The main risks for ALR Technologies Inc. include intense competition in the diabetes care market, potential regulatory changes affecting their products, and the impact of economic downturns on healthcare spending. Additionally, the company faces the risk of technological obsolescence as glucose monitoring technology rapidly advances. The company's negative P/E ratio and profit margin also pose significant financial risks, raising concerns about its ability to sustain operations and achieve profitability. The OTC listing adds further risks related to liquidity and disclosure.
What revenue streams does ALR Technologies Inc. have in healthcare?
ALR Technologies Inc.'s revenue streams are derived from several key areas within the healthcare sector. These include sales of their Diabetes Management System to healthcare providers and insurance companies, revenue from the sale of Continuous Glucose Monitoring (CGM) devices for human use, and sales of the GluCurve Pet CGM to veterinary clinics and pet owners. Additionally, the company generates revenue from subscriptions to its Prediabetes System, which provides educational content and community support for individuals at risk of developing diabetes. The relative contribution of each revenue stream is not publicly available.
How does ALR Technologies Inc. address competition from larger medical device companies?
ALR Technologies Inc. addresses competition from larger medical device companies by focusing on niche markets and specialized solutions. Their GluCurve Pet CGM, for example, targets the veterinary market, providing a specialized solution for diabetes care in pets. Additionally, ALRT's Diabetes Management System offers a comprehensive approach to diabetes care, integrating data collection, predictive analytics, and remote monitoring. By focusing on specific market segments and offering integrated solutions, ALRT aims to differentiate itself from larger competitors and establish a competitive advantage.
What are the key factors to evaluate for ALRT?
ALR Technologies Inc. (ALRT) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does ALRT data refresh on this page?
ALRT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALRT's recent stock price performance?
ALR Technologies Inc. (ALRT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive Diabetes Management System. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- Analyst coverage is limited, making it difficult to assess market sentiment.
- OTC market investments carry higher risks than exchange-listed securities.